English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
Compass Pathways and the Rise of Corporate Psilocybin: What It Means for Retreat-Seekers
Here's a story that explains a lot about where psychedelic medicine is heading. A mother, a physician, watches her son collapse under the weight of OCD and depression. She reads everything. One night she stumbles on a small 2006 study suggesting psilocybin — the compound in magic mushrooms — might quiet the obsessive loops that conventional medicine couldn't touch. She finds an underground guide. Her son drinks the tea. Six hours later, something shifts. He goes back to school. He gets his life back. That family went on to launch a company now worth roughly $400 million, listed on the Nasdaq, running one of the largest psilocybin trials in history. For anyone researching ayahuasca, psilocybin, or other plant medicines as a way out of addiction, depression, or trauma, the rise of Compass Pathways is worth understanding. It's reshaping the whole landscape — including the retreat world you're probably reading about right now. The origin story matters because it explains the tension. Ekaterina Malievskaia and George Goldsmith weren't pharmaceutical executives. They were parents. After watching their son emerge from a single supervised psilocybin session looking like himself again — sleeping, exercising, returning to class — they did what desperate, well-resourced parents do. They threw money at the problem. Hundreds of thousands of dollars into psychedelic nonprofits. A small project on the Isle of Man offering psilocybin to hospice patients. A nonprofit called C.O.M.P.A.S.S. to bring these treatments to people who'd run out of options. Then, in 2016, they pivoted. The nonprofit shut down. A for-profit corporation launched in London. The reasoning, as they tell it: you cannot move a drug through regulatory approval on donations alone. The price tag for late-stage trials runs into the hundreds of millions. To reach the people who needed psilocybin most — the ones whose insurance might one day cover it — they needed venture capital, not philanthropy. That pivot didn't sit well with everyone. Several researchers and longtime advocates who'd helped them in their nonprofit days felt blindsided. Some still do. The argument that follows them around — that you can't ethically commercialize a sacrament — is one the company has spent years answering. By 2017, three names had quietly placed bets on Compass: Christian Angermayer (a German entrepreneur who'd had his own psilocybin experience and become an evangelist), Michael Novogratz (the crypto investor), and Peter Thiel (the PayPal cofounder). Each put in roughly a million pounds. Novogratz's framing was almost charmingly blunt — he'd taken a flyer on cryptocurrencies and made a fortune, so why not a flyer on something equally fringe? The money kept coming. A £25 million round in 2018. An $80 million Series B in 2019, then a record for the sector. A Nasdaq IPO in 2020 at a billion-dollar valuation. The company is now running a Phase 3 trial with nearly a thousand participants, testing a synthetic form of psilocybin (they call it COMP360) against treatment-resistant depression — the cases where SSRIs, talk therapy, and everything else have already failed. Analysts have floated peak sales numbers somewhere between $1.1 billion and $8 billion if the drug clears approval and gets expanded for other mental-health conditions. The first approvals could land as early as 2026. That's not a footnote. That's the medical mainstream walking into a room it's been locked out of since the 1960s. You might be wondering why a story about a publicly traded pharmaceutical company matters if you're researching, say, an ayahuasca retreat in Peru or a psilocybin ceremony in Jamaica. Fair question. Here's the honest answer: the two worlds are bleeding into each other, and the choices you make as a retreat-seeker are going to be shaped by what happens in those clinical trials over the next two years. A few things are likely to shift: This is the question I get asked most often by people deciding whether to book. The answer isn't binary, and anyone who tells you it is — on either side — is selling something. Plant medicine, when it works, doesn't work because the molecule is magic. It works because the molecule cracks something open, and what you do with the opening matters more than the opening itself. The single session that turned Allan Malievsky's life around wasn't just six hours of psilocybin. It was a darkened room, a trusted guide, music chosen with care, and — crucially — a family ready to support whatever came next. The medicine was the catalyst. The container was the cure. This is why master plants — ayahuasca, peyote, San Pedro, iboga, the whole lineage — have always been used inside ritual frameworks. The Shipibo curanderos in the Peruvian Amazon haven't been running clinical trials, but they have been refining a practice over generations. There's wisdom there that no Phase 3 protocol can replicate. There's also, let's be honest, plenty of charlatanism out there too. Both things are true. If you're weighing a retreat, a few honest filters worth running: Compass has earned its share of critics, and the criticism is worth understanding before you form an opinion. Some of it centers on patent applications that activists argued were overreaching — attempts, they said, to lock down techniques that the broader community considered shared heritage. Some of it is more philosophical: the discomfort with anyone profiting from substances that Indigenous communities have stewarded for centuries without commercial interest. You can think both things at the same time. You can be glad that millions of people with treatment-resistant depression may soon have a real option, and uneasy about the consolidation of plant medicine into corporate IP portfolios. The retreat world tends to live closer to the older, communal model. The clinical world is heading somewhere very different. Where you land on that spectrum will shape what kind of healing path makes sense for you. Read more than the marketing. Talk to people who've actually sat in ceremony — not the ones writing breathless trip reports, but the ones who can tell you what their life looked like six months later. Pay attention to whether they sound like they're still chasing the experience or whether they've integrated it and moved on. The second group is who you want to learn from. And give yourself permission to wait. The clinical trials will keep running. The retreats will still be there next year. If you're in acute crisis, that's a different conversation — find a clinician, find support, don't make a major decision while drowning. But if you're in the careful research phase, careful is good. This is real medicine, and real medicine deserves real preparation. If something here resonates and you want to see what's actually available, a range of curated ayahuasca and psilocybin retreats can be browsed on our marketplace here. Take your time. The right container matters as much as the medicine itself.
Why a Failed Ketamine Trial Doesn't Spell Doom for Psychedelic Medicine
Earlier this year, one of the most-watched companies in the psychedelics space stumbled badly. A mid-stage clinical trial of a ketamine-based depression drug — the kind of study that's supposed to validate years of investor faith — missed its targets. The stock tanked. Headlines piled on. And a lot of people who'd been quietly hopeful about psychedelic medicine reaching the mainstream felt that familiar sinking feeling: here we go again. So is the dream dead? Not even close. But the story is more complicated than the press releases suggest, and if you're someone considering ayahuasca, psilocybin, or any other plant medicine for your own healing, it's worth understanding what actually happened — and what it doesn't tell you. The drug in question, an intranasal ketamine analog being developed for treatment-resistant depression, didn't outperform placebo in the way researchers hoped. That's a real disappointment for the patients who participated, the scientists who designed the trial, and the shareholders who were banking on a win. The CEO of the parent company has been telling anyone who'll listen that the broader pipeline is still strong — seven compounds, multiple targets, both psychedelic and non-psychedelic. He may well be right. But here's what the failed trial does not mean: it does not mean ketamine doesn't help with depression. It does not mean psilocybin won't either. And it certainly doesn't mean the wider movement around psychedelics, master plants, and plant-medicine-based healing has run out of road. One isolated drug, in one specific formulation, at one specific dose, in one specific population — that's what failed. The category is alive and well. If anything, the setback is a useful reminder that turning a powerful experience into a standardized pharmaceutical product is genuinely hard. The thing that makes ayahuasca or psilocybin so transformative in ceremony — the set, the setting, the integration, the relational container — is often exactly what gets stripped out when you're trying to file an FDA application. That's not the medicine's fault. That's the model. There are basically two routes by which psychedelics are reaching people who need help. One is the corporate biotech path: synthesize the molecule, run the trials, get FDA approval, dispense it in a clinic with a trained therapist for a few hundred dollars a session (or a few thousand, depending). The other is the retreat path — traveling to Peru, Costa Rica, Mexico, the Netherlands, or wherever the legal and cultural conditions allow, and sitting with the medicine in something closer to its traditional context. Both paths have real merit. Both have real drawbacks. The pharmaceutical route promises rigor, insurance coverage (eventually), and the comfort of a regulated environment. The retreat route promises depth, ceremony, community, and access to master plants that no clinical trial is ever going to bottle. Most people I've talked with who've done both will tell you they're different experiences entirely — not better or worse, just different animals. The trial failure highlights something practitioners in the retreat world have been saying for years: the substance alone isn't the medicine. A ketamine infusion in a beige clinic is not the same intervention as a psilocybin journey in a forest with a skilled facilitator and three days of integration afterward. Pretending they're the same — pretending a molecule is the entirety of the healing — has always been a stretch. If you've been researching ayahuasca retreats, ibogaine programs, or psilocybin journeys, here's the honest answer: probably not. The biotech industry's quarterly earnings have very little to do with whether a ceremony is right for you, what addiction recovery looks like with plant medicine, or how a master plant might or might not help with the depression that's been sitting on your chest for years. What the news should change is your tolerance for hype. Psychedelics are not a guaranteed cure. Ayahuasca is not a guaranteed cure. Ibogaine is not a guaranteed cure. The best retreat operators I know are quite clear about this — they'll tell you straight that some people have profound breakthroughs, some people have hard nights and walk away with mixed feelings, and a few people don't get what they came for at all. Anyone promising you a miracle is selling something. Here are some questions worth sitting with before you book anything: One of the most compelling reasons people are still drawn to plant medicine, despite the choppy news cycle, is its track record with addiction. Anecdotal reports — and a growing pile of preliminary research — suggest that ibogaine can interrupt opioid dependence in ways nothing else quite manages. Ayahuasca has helped people reconfigure their relationship with alcohol, cocaine, and various other substances they thought they'd carry forever. Psilocybin has shown promise with tobacco. None of this is a magic bullet, but it's also not nothing. The traditional concept of master plants — the idea that certain plants are teachers, with their own intelligence and curriculum — sits awkwardly inside a clinical-trial framework. You can't really run a placebo-controlled study of a relationship. And yet that's often what people describe after working with these medicines: less a drug experience and more an encounter with something that has its own intentions for you. Take that for whatever it's worth, but it's a thread running through thousands of years of indigenous practice and decades of contemporary retreat work. What the biotech setbacks underscore is that the institutional path is going to be slow, uneven, and full of these dramatic dips. The retreat world, meanwhile, has been operating in parallel — quieter, less venture-backed, and in many cases more grounded in the lived reality of what these substances actually do for people. If you're at the stage of seriously weighing whether to attend a retreat, the failed trial is essentially a footnote. The decision in front of you is much more personal: do you have the time, the resources, the support network, and the genuine readiness to do this work? Have you done your reading? Have you talked to people who've done it before — both the evangelists and the skeptics? Take your time choosing. The good operations have waiting lists, careful screening, and facilitators with years of training. The sketchy ones will take anyone with a credit card. That alone tells you most of what you need to know about where to look. For readers who want to take this further, a curated range of plant-medicine retreats — ayahuasca, psilocybin, ibogaine, and related programs — can be browsed on our marketplace here. Markets will move. Trials will succeed and fail. Companies will rise and stumble and rise again. The medicines themselves, and the people who've been working with them carefully for generations, are not going anywhere.
Ibogaine Visions and the Question of Reincarnation: What People Actually See
Somewhere around hour six, people start describing things they have no business knowing. A village they’ve never visited. A death they didn’t die. A face that feels more familiar than their own mother’s. Ibogaine does this. It’s one of the strangest features of an already strange medicine, and if you’re researching it seriously — maybe for an addiction, maybe for something heavier you can’t name — you’re going to run into the reincarnation reports sooner or later. So let’s talk about them honestly. Not as proof of anything cosmic, not as hallucinations to dismiss, but as a real thing that happens to real people in ibogaine ceremonies and clinics around the world. What the visions tend to look like. Why they hit so hard. And what to do with them once you’re back on your feet. Ibogaine is an alkaloid extracted from the root bark of the iboga shrub, used for generations in Bwiti spiritual practice in Gabon and now studied internationally for opioid and stimulant addiction. It’s not recreational. There’s no euphoria to chase. A full flood dose lays you flat for twelve to thirty-six hours and walks you through what practitioners often call a “waking dream state” — long, narrative, dense with autobiography. The first phase is usually visual. People describe a film reel: scenes from their childhood, half-forgotten arguments, the face of someone they hurt, the body they had at seven. The second phase shifts inward — quieter, more cognitive, more like sorting through a filing cabinet with the lights on. Somewhere in those phases, a subset of people report something else entirely. They report being someone else. You’ll find these stories on forums, in clinic testimonials, in the older Bwiti ethnographies, and in the quiet conversations after a ceremony when nobody’s recording anything. They share a strange consistency. Someone lies down a 41-year-old software engineer from Berlin and meets, for hours, a 19-year-old conscript in a war that ended generations ago. They feel the mud. They feel the fear. They feel the moment of dying. And then they wake up still themselves, still 41, but rearranged. Common features of these visions: Whether these are literal past lives, archetypal memories, ancestral echoes, or the brain doing something extraordinary with its own material — the honest answer is nobody knows. Ibogaine researchers tend to call them autobiographical or symbolic; Bwiti elders would call them visits with ancestors; the person who had the vision usually doesn’t care what we call them, because the experience itself is so vivid it bypasses the question. Ayahuasca gives you cosmic geometry and serpents. Psilocybin gives you ego dissolution and the feeling of being woven into everything. Ibogaine, more than any of them, gives you narrative. Long, coherent, autobiographical narrative. People describe it less as tripping and more as watching a documentary about themselves — or, sometimes, about someone they were before. A few theories on why: None of this proves reincarnation. It does suggest why ibogaine, of all the plant medicines, is the one most likely to drop you into someone else’s life for an evening. Here’s the part that matters if you’re actually considering iboga work. The reincarnation vision, whatever it is metaphysically, tends to do real work. People who arrive at a clinic to treat heroin addiction sometimes come out the other side talking about a life they lived in 1840 — and also, separately, find that the craving is gone. The two things aren’t necessarily related. But they aren’t unrelated either. What I’ve heard, again and again, is that the vision gave the person a frame for pain they couldn’t previously locate. A man who couldn’t explain his terror of water meets, on ibogaine, the body of someone who drowned. He doesn’t become a believer in past lives. He just finds, afterward, that he can swim. A woman with a self-destructive pattern she’d worked on for a decade sees, in vision, a life ended by violence she didn’t cause and couldn’t prevent. The pattern loosens. Whether that’s healing through symbol or healing through literal memory, the loosening is real. This is part of why ibogaine has earned its reputation in addiction recovery — not just for interrupting the neurochemistry of dependence, but for handing people a story large enough to hold what they’ve been running from. The plant medicine community sometimes calls these the “master plants” for exactly this reason. They teach. Iboga teaches in long, autobiographical paragraphs. If you have one of these experiences — or if you’re reading this because someone you love did — a few practical thoughts from people who’ve worked this territory: The worst outcomes I’ve seen aren’t from the visions themselves — they’re from people who either build an identity around being the reincarnation of someone famous (please don’t) or who shove the whole experience in a drawer because it doesn’t fit their worldview. Both lose the gift. Reincarnation visions sound romantic. The medicine that produces them is not. Ibogaine carries genuine cardiac risk and has been associated with fatalities, almost all linked to undiagnosed heart conditions, drug interactions, or unsupervised use. This is not a substance to take in a friend’s basement. A reputable ibogaine clinic will require an EKG, bloodwork, a full medication review, and medical monitoring throughout the session. If a provider isn’t asking about your heart, walk away. If you’re considering iboga for addiction recovery specifically, look for facilities with medical staff on site, transparent screening protocols, integration support after the experience, and honest communication about what ibogaine can and can’t do. It’s not a magic bullet. It’s a doorway, and what you do on the other side of it matters more than the doorway itself. For readers who want to take this further, a curated range of ibogaine and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide — whether the right next step is a clinic, more reading, or simply sitting with the question a while longer — give the decision the weight it deserves. Visions of past lives are not the strangest thing iboga will hand you. The strangest thing is how ordinary your current one starts to feel afterward, and how much of it suddenly seems worth showing up for.
Where Psychedelic Medicine Is Headed: Five Predictions Worth Knowing
The psychedelics conversation has shifted. A few years ago, asking a doctor about psilocybin would have earned you a raised eyebrow and maybe a referral. Now there are publicly traded psychedelic companies, billion-dollar valuations, FDA breakthrough designations, and state-level legalization rolling out in real time. If you’re someone weighing a retreat — quietly wondering whether ayahuasca, psilocybin, or another master plant might help with the depression, addiction, or stuck pattern you can’t seem to shake — the ground under you is moving fast. So where is all of this actually going? I’ve been tracking the industry, sitting in ceremonies, and talking to facilitators and investors for years now. A handful of clear themes keep surfacing — and they matter, because they shape what kind of psychedelic healing will be available to you in three years, five years, ten. Here’s an honest read on what’s coming. There are two psychedelic worlds running in parallel right now, and they barely speak. One is the clinical pipeline — pharma companies, FDA trials, standardized dosing, therapists in carpeted offices. The other is everything else: the Shipibo curanderos in the Peruvian Amazon, the underground guides in Brooklyn apartments, the Bwiti iboga practitioners in Gabon, the decriminalization activists in Denver and Oakland. One side has the data and the money. The other side has thousands of years of accumulated practice and, frankly, most of the wisdom about how these substances actually work on a human soul. Several leaders in the field have pointed out — correctly, in my view — that the wall between these worlds is doing nobody any favors. The medical track could learn enormous amounts from traditional preparation, dieta, and integration. The underground could benefit from rigorous safety standards and harm reduction data. What I think we’ll see over the next five years is messy convergence. Not a clean merger — these worlds are too different — but more cross-pollination. More retreats hiring licensed therapists. More clinics borrowing ceremony elements. And more honesty from both sides about what the other does well. For the past few years, venture funding in psychedelics has been overwhelmingly aimed at drug development — new molecules, new patents, new delivery mechanisms. That’s starting to shift. Several investors I respect have been saying the next wave of capital will go into the boring-but-essential stuff: clinics, training programs, integration platforms, insurance pathways. Here’s why that matters to you. Even if the FDA approves psilocybin-assisted therapy for depression tomorrow, you can’t use it unless there are trained therapists in your city, a clinic that takes your insurance, and an aftercare program that doesn’t cost your monthly rent. The molecule is the easy part. The system around the molecule is the hard part. The bottleneck nobody talks about enough is the human one. By some estimates, the field needs tens of thousands of trained psychedelic therapists this decade just to meet projected demand for MDMA and psilocybin treatment. We’re not close. A retreat you book in 2026 — even at a reputable center — may still have facilitators who learned through apprenticeship rather than any formal credential. That’s not necessarily bad. Traditional lineages have trained people brilliantly for centuries. But it does mean you have to do your homework. This is the question I get asked most often, and there’s no single answer. But there are filters worth applying before you wire money to anywhere. The good news: the marketplace is maturing. Five years ago, you mostly had to ask around in person to find a reputable place. Now there’s real comparison, real reviews, real accountability. Drug development is brutal. Most biotech companies that start clinical trials never make it to market, and there’s no reason to expect psychedelics to defy that math. Over the next few years, plenty of well-funded, well-publicized psychedelic startups are going to quietly disappear. Some will fold their programs. Some will pivot. A few will get acquired. This will look, in headlines, like the field collapsing. It isn’t. It’s the normal washout that happens in any new industry — a clearing of the field that leaves behind the operators who actually have something durable. The companies that survive will likely be the ones who took preparation, set, setting, and integration seriously rather than treating psychedelics as just another pill. For you as a potential retreat-goer, this matters less than it sounds. The retreats themselves — especially the established ones in Peru, Costa Rica, the Netherlands, Mexico, Jamaica — operate largely outside this corporate churn. Traditional plant medicine has been running for a long time without any quarterly earnings calls. The cultural shift is real. Ten years ago, telling your boss you were taking a week off for an ayahuasca retreat would have been career-limiting. Today, in plenty of industries — tech, creative work, healthcare ironically enough — it’s become almost mundane. Therapists are getting trained. Veterans’ groups are openly advocating for MDMA-assisted therapy. Athletes and executives talk about plant medicine on podcasts. But don’t mistake the cultural shift for the legal one. Ayahuasca is still federally illegal in the United States outside of religious exemptions. Psilocybin remains Schedule I almost everywhere. Oregon and Colorado are early experiments, not the national norm. Most people who want to work with these medicines still have to either leave the country or operate in legal gray zones at home. What’s changing is the texture of the conversation. People are less embarrassed. Doctors are more curious. The phrase “plant medicine” has stopped sounding fringe to anyone under fifty. That cultural permission slip is part of why retreats are filling up — and part of why the quality of what’s on offer has gotten much better. Demand creates options. If you’re reading this because you’re considering a retreat — for addiction, for depression, for trauma, for the sense that something in your life is asking to be looked at — here’s the honest framing. The industry is professionalizing, but it isn’t finished. The science is encouraging, but it isn’t settled. The legal landscape is opening, but slowly and unevenly. Some retreats are excellent. Some are not. The work itself, when it lands, can be genuinely life-rearranging, but it isn’t magic and it isn’t guaranteed. What I can say with confidence: people who do this carefully — with proper screening, a reputable facilitator, real integration support, and clear intentions — tend to come back changed in ways that hold up over years, not weeks. People who treat it like a vacation or a bucket-list item tend to get a vacation. The variable that matters most isn’t the medicine. It’s how seriously you take the container around it. If any of this has landed somewhere in you, the next move isn’t booking — it’s researching. Read the published trial data. Talk to people who’ve sat in ceremony at the place you’re considering. Ask hard questions and notice how the retreat answers them. When you’re ready to compare specific options, a curated selection of vetted psychedelic and plant-medicine retreats can be browsed on our marketplace here. Take your time. The medicines aren’t going anywhere, and the right retreat is worth waiting for.
Microdosing Psychedelics: An Honest Look at What the Research Actually Shows
A friend once told me she'd been microdosing psilocybin for six weeks and felt like the volume knob on her anxiety had been turned down by about a third. Not silenced. Just turned down. That's the kind of report you hear constantly in this corner of the psychedelic world — quiet, modest, hard to verify, and oddly compelling. Microdosing psychedelics has moved from Silicon Valley curiosity to mainstream conversation over the past few years, and the questions I get from readers researching plant medicine almost always include some version of: should I try this before committing to a full ceremony? Fair question. Let's get into what microdosing actually is, what the science says, and what it doesn't. A microdose is what researchers politely call a sub-perceptual dose — small enough that you don't feel high, don't see walls breathing, don't have any of the textbook psychedelic experiences. You can drive. You can answer emails. You can sit through a meeting without anyone suspecting a thing. That's kind of the whole point. Roughly speaking, a microdose lands somewhere between a tenth and a twentieth of a recreational dose. For the most common substances people use, that works out to: Finding your dose is genuinely a trial-and-error process. People who are sensitive to serotonergic compounds can feel noticeable effects at amounts that another person wouldn't register at all. The rule of thumb most experienced microdosers follow: if you can feel it, you took too much. A proper microdose should slide under your perception, not announce itself. The protocol most people reference comes from researcher James Fadiman, who suggested dosing once every three to four days for around ten weeks, then taking a break. The logic is partly about tolerance — psychedelics build it fast — and partly about not letting the practice become invisible background noise. Others run shorter cycles, or use a two-days-on, one-day-off rhythm. There's no single right answer, and frankly, anyone who tells you there is hasn't been paying attention. The reasons cluster into two broad camps. The first is mental health — people dealing with depression, anxiety, PTSD, ADHD, or OCD who either haven't responded well to conventional medication or don't love the side effects that come with it. The second is what you might call optimization — focus, creativity, energy, mood, the feeling of being a little more present and a little less stuck in your own head. The mental health angle is where things get interesting, and where I see the most readers genuinely curious. If you've been on SSRIs for a decade and you're tired of feeling emotionally flattened, the idea of a sub-perceptual dose of psilocybin twice a week sounds appealing. Journalist Erica Avery wrote publicly about microdosing LSD lifting her out of a depressive episode, and writer Ayelet Waldman built a whole book around her experience doing the same. Waldman's depression stayed gone after she stopped. Avery's came back — and she eventually concluded that occasional larger doses worked better for her than ongoing small ones. Which is the most honest thing anyone can say about this practice: your mileage will vary. Dramatically. Here's where I have to put on my skeptic hat, because the gap between what people report anecdotally and what controlled studies have found is bigger than the microdosing community generally admits. The obvious worry with any sub-perceptual practice is that the effects are mostly placebo. You believe the tiny dose will help, so it does. That's not nothing — placebo effects are real and clinically significant — but it matters for the question of whether the molecule itself is doing anything. A double-blind, placebo-controlled trial published in Biological Psychiatry in 2019 tried to answer this. Researchers gave healthy volunteers LSD at 6.5, 13, and 26 micrograms versus a placebo. They found dose-related effects on subjective experience — feelings of vigor went up, but so did anxiety. Creativity scores actually got worse on LSD. Cognitive performance didn't improve. None of which lines up neatly with the rosy reports you read online. One of the researchers noted that benefits might only show up after repeated dosing over time, which the study didn't measure. And the 26-microgram dose is arguably no longer a microdose at all — most harm-reduction guides classify it as a low recreational dose. So the picture is muddier than either side of the debate likes to admit. Fadiman ran a much larger observational study with over a thousand participants across 59 countries. People microdosing LSD or psilocybin roughly every three days reported improvements in mood, productivity, focus, energy, relationships, and health habits. Some had even tapered off antidepressants in favor of microdosing. Encouraging — but it's a self-report study with no control group. Fadiman himself was careful to note that people whose primary issue is anxiety probably shouldn't microdose, because some users find it amps anxiety up rather than down. That tracks with the controlled trial. A 2019 rodent study found that microdoses of DMT given over seven weeks improved measures of depression and anxiety without messing with cognition. Promising, but it's rats, not people, and the leap from rodent brain to human depression is famously treacherous. We don't have meaningful human data on microdosing DMT for mental health yet. A few things I think are worth saying plainly: This is probably the question that matters most for readers weighing a retreat. Microdosing and ceremonial plant medicine are different tools doing different jobs. A microdose is a quiet nudge to your nervous system, maybe useful for taking the edge off a difficult month or unsticking a creative block. A full ayahuasca ceremony, or a psilocybin retreat with experienced facilitators, is something else entirely — a full confrontation with whatever you've been carrying. People recovering from addiction, in particular, tend to find that microdosing alone doesn't get them where they need to go. The research on psychedelics and addiction recovery — the work on ibogaine for opioid dependence, psilocybin for alcohol use disorder, ayahuasca for trauma underlying substance use — involves full doses in carefully held settings, not sub-perceptual experiments at the kitchen table. That said, some people use microdosing as a gentle on-ramp. A way to develop a relationship with these compounds and notice how their own system responds before committing to a multi-day retreat. There's logic to that, as long as you're honest about what microdosing can and can't do. If you're chronically anxious, on psychiatric medication, or already suspect you're someone who reacts strongly to substances, the honest answer is probably no — or at least not without serious thought and ideally a clinician who knows what you're up to. If you're a generally stable person curious about what a slightly quieter mind might feel like, and you have access to reliable material, it might be worth a careful experiment. Start lower than the standard protocol. Keep a journal. Take real breaks. Pay attention to what changes and what doesn't. And if what you're really looking for is the deeper work — the kind that addresses trauma, addiction, or the persistent sense that something in your life is stuck — microdosing is unlikely to be the whole answer. For readers who want to explore the fuller path, a curated range of psychedelic and plant-medicine retreats can be browsed on our marketplace here. Whatever direction you go, go slowly. These compounds reward patience and humble the people who don't bring it.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
Cacao Ceremony: What It Really Is, How It Feels, and Why It Matters
The first time I drank ceremonial cacao, I was sitting on a damp log in a pine forest in Maine, full moon overhead, expecting something resembling hot chocolate. What landed in my wooden cup was darker, grittier, and considerably more bitter than anything I'd associated with the word “chocolate.” I sipped it anyway. An hour later, I understood I'd been drinking the wrong cacao my entire life. This isn't a story about a psychedelic blowout. Cacao isn't ayahuasca. It won't dissolve your ego or send you spiraling through fractal jungles. But for a lot of people moving through the broader world of plant medicine and psychedelic healing, cacao has become a kind of gentle on-ramp — a way to learn what it feels like to sit in ceremony, drop into the body, and meet a plant with respect before encountering something stronger. If you're researching retreats and you keep seeing cacao mentioned alongside ayahuasca, San Pedro, and psilocybin, here's what's actually going on. A cacao ceremony is a ritual gathering — usually in a circle, often around a fire or altar — where participants drink a strong dose of ceremonial-grade cacao prepared with intention. There's typically a facilitator or shaman holding the space. There may be songs, prayers, silence, breathwork, journaling, or movement. The specifics vary wildly depending on the lineage and the facilitator's training. The cacao itself is the centerpiece, and this is where most newcomers get tripped up. Ceremonial cacao is not the cocoa powder in your pantry. The cacao fruit is harvested in Central or South America, fermented to strip away the pulp, and the beans are ground whole into a thick paste. Nothing is removed. No fats stripped out, no alkaloids isolated, no sugar dumped in. It's the full, unaltered plant. The comparison I keep coming back to: store-bought cocoa is to ceremonial cacao what a fast-food orange juice pouch is to a freshly squeezed orange. Same family. Different universe. Cacao has been used ceremonially for thousands of years across what we now call Mexico, Guatemala, Belize, and Honduras. The Maya and Aztec civilizations treated it as sacred — a food for royalty and a medicine for ritual. It appeared in marriage ceremonies, in offerings to deities, in funerary rites. The word "cacao" itself traces back to Mesoamerican languages, and archaeological residue testing has found cacao traces in ceremonial vessels dating back over three millennia. The modern revival, mostly Western-led and concentrated around facilitators in Guatemala, Bali, Costa Rica, and the U.S. wellness scene, is a more recent phenomenon. Some of it honors the original traditions carefully. Some of it doesn't. As with any plant medicine making the leap from indigenous context to global retreat circuit, there's a wide spectrum of integrity out there. Worth knowing before you book. No. Not in the way ayahuasca, psilocybin, or ibogaine are psychedelic. You won't hallucinate. You won't lose your sense of self. You won't see geometric patterns or commune with entities from other dimensions. If that's what you're after, cacao isn't your medicine. What cacao does is more subtle, and that subtlety is exactly why some people dismiss it and others swear by it. The active compounds — theobromine, anandamide, phenylethylamine, magnesium, a small amount of caffeine — work together to gently elevate mood, increase blood flow, soften the nervous system, and open up emotional access. Theobromine is a vasodilator; you'll often feel warmth spreading through your chest within twenty or thirty minutes. Anandamide is sometimes called the “bliss molecule.” Phenylethylamine is associated with feelings of attraction and connection. Put that together in a ceremonial dose (usually 30 to 45 grams of pure cacao paste, far more than a chocolate bar) and you get a state that's hard to describe but easy to recognize once you've felt it: alert but not wired, soft but not sleepy, emotionally accessible without being overwhelmed. People cry. People laugh. People sit silently for two hours and report feeling fundamentally rearranged afterward. A lot of facilitators in the broader plant medicine world use cacao as a complementary practice. There are practical reasons for this: This is part of why cacao retreats and cacao ceremonies are increasingly stitched into broader plant medicine programming, especially in places like Guatemala's Lake Atitlán region, Costa Rica's Nicoya Peninsula, and parts of Bali. Every facilitator does this differently, but the rough arc tends to look something like this. You arrive, leave your shoes at the door, and find a cushion in the circle. There's usually an altar in the center — flowers, candles, sometimes crystals or feathers, sometimes nothing more than a single carved wooden bowl. The facilitator opens the space, sets intentions, may invoke directions or sing an opening song. Then the cacao is served, cup by cup, often with eye contact and a quiet exchange. You sit with your cup. You set your own intention — what you're sitting with, what you're asking for, what you want to release. You drink. The next two to four hours are loosely held. There might be guided meditation, ecstatic dance, sharing circles, breathwork, or extended silence. The facilitator's job is to hold the container, not to direct your experience. You go where the medicine takes you, which for cacao usually means somewhere quieter and more emotionally honest than your day-to-day mind. Cacao is broadly safe, but it isn't for everyone. A few honest caveats: The cacao world ranges from deeply traditional Maya-rooted ceremonies led by indigenous abuelas in Guatemala to weekend wellness pop-ups in converted yoga studios run by someone who took a five-day training. Both can be meaningful. Neither is automatically legitimate just because it's labeled “ceremony.” A few things to look for: For readers who want to take this further, a range of curated cacao and plant medicine retreats can be browsed on our marketplace here. Whether cacao becomes a standalone practice or a doorway into deeper psychedelic and plant medicine work, the value is the same: you learn what it feels like to actually sit with a plant, ask it something, and listen to what comes back.
Inside the Psilocybin Microdosing Boom: What Founders, Doctors, and Researchers Actually Say
Somewhere between the third espresso and the fourth Slack message, a quiet experiment is unfolding in the tech world. Founders, VCs, and operators — people who would happily debate Series A term sheets at midnight — are dropping crumb-sized amounts of psilocybin into their morning routine and reporting back like amateur neuroscientists. Welcome to the so-called shroom boom, where ayahuasca, psychedelics, addiction recovery conversations, and the older idea of master plants are colliding with the productivity industrial complex. It’s a strange moment. Magic mushrooms — the same fungi that defined a generation of 1960s counterculture — are now being microdosed before pitch meetings. Whether that’s a genuine evolution in human wellness or a tech-bro repackaging of an ancient sacrament depends on who you ask. So let’s actually ask. A microdose is small. Really small. Researchers like Dr. James Fadiman, who has spent decades documenting the practice, define it as roughly one-twentieth to one-tenth of a recreational dose — enough to nudge the nervous system, not enough to send you into the cosmos. You don’t hallucinate. You don’t see the walls breathe. Ideally, you barely notice anything other than feeling a touch more present. People microdose all sorts of substances: psilocybin mushrooms, LSD, occasionally cannabis, and in rarer cases sub-perceptual amounts of DMT or even ayahuasca tinctures. Psilocybin is by far the most popular because it’s organic, relatively forgiving, and — at the moment — culturally fashionable. Protocols vary. Some follow Fadiman’s one-day-on, two-days-off cycle. Others do two days on, five off. A few people just take it when they feel like it, which researchers tend to politely call “not a protocol.” And no, it’s not the same as sitting in a ceremony with a curandero and drinking a cup of brewed master plants for eight hours. A microdose is the opposite experience — quiet, undramatic, almost boring. That’s the point. The anecdotal case is consistent enough to be interesting. Founders describe sharper focus, less anxious chatter, a sense of being able to listen properly in conversations. One beverage entrepreneur in Florida told reporters that after he started microdosing, he found himself less reactive and more open — fewer doses of caffeine, fewer panicked spirals between meetings. A Los Angeles wellness founder calls her routine a “nano-dose,” about an eighth of a full dose, taken a few mornings a week. She says it dissolves anxiety the way a hot bath dissolves muscle tension. A former Canadian finance consultant turned psychedelic educator put it most bluntly: microdosing, she says, let her get three days of work done in one. She’s now built a small business around teaching others to do the same. You hear a few themes again and again from people who microdose seriously: That last one is interesting. Microdosers often say the effect compounds across the week, rather than living and dying inside the dose itself. Whether that’s real or a story they’re telling themselves is exactly where the science gets wobbly. Here’s the honest version. Macro-dose psilocybin research — full ceremonial doses given in clinical settings — is genuinely promising. There are well-designed trials showing meaningful effects on treatment-resistant depression, end-of-life anxiety, and addiction recovery, particularly for alcohol and nicotine dependence. That body of work is one of the reasons psychedelics, addiction, and mental-health treatment now share so much real estate in medical journals. Microdosing is a different story. The randomized, double-blind studies that do exist tend to show modest effects, much of which can be explained by expectation. As one Harvard-affiliated physician researcher has pointed out, almost everyone who microdoses believes it helps them, but the trials don’t cleanly confirm it. Creativity, focus, presence — these aren’t cholesterol levels. They’re slippery to measure. The gold-standard trial design doesn’t translate well to subjective wellness gains. That doesn’t mean microdosing is fake. It means we’re early. The psychedelic research renaissance has had perhaps two decades of serious momentum, and most of that funding has gone toward the more dramatic, easier-to-measure clinical applications. Microdosing science is still catching up. Under United States federal law, psilocybin is a Schedule I controlled substance. Possession is illegal. That’s the headline. The fine print is more interesting: Oregon allows supervised adult use through licensed service centers, Colorado has moved in a similar direction, and cities including Denver, San Francisco, Oakland, Seattle, and Minneapolis have decriminalized personal possession to varying degrees. Several state-level legalization efforts have stalled. Canada, meanwhile, is racing ahead with a patchwork of clinics, retreats, and brick-and-mortar mushroom shops operating in legal grey zones. So legality depends entirely on where you’re standing when you swallow the capsule. None of this is legal advice — please do your own homework based on your jurisdiction. As for safety, microdosing is generally considered lower-risk than full-dose use, but “lower risk” doesn’t mean “no risk.” A few honest caveats worth knowing: For a lot of people, microdosing isn’t the destination — it’s the doorway. Curious about psilocybin in small amounts, they eventually start reading about full-dose experiences, about ayahuasca, about the long-standing traditions of plant medicine and master plants in the Amazon and the Andes. That’s a meaningful step up in intensity, and it deserves a different kind of preparation. If you’re weighing a retreat — psilocybin, ayahuasca, San Pedro, or something else in the plant-medicine family — a few things are worth thinking about before the credit card comes out. Who runs the retreat? What lineage or training do the facilitators come from? What’s the medical screening process? What does integration support look like in the weeks after you fly home? Is there a real container around the experience, or is it essentially a vacation with a substance attached? The good retreats tend to ask you as many questions as you ask them. The questionable ones take your deposit before they’ve learned your last name. A retreat is not a productivity hack. It’s an experience that can reshape how you see your life, and the people guiding it matter enormously. There’s a strange double life happening in tech right now. Some founders talk openly about their psilocybin practice on podcasts. Others won’t mention it out loud, even with VCs they suspect are doing the same thing. The 2021 firing of an Iterable CEO who admitted to dosing LSD before a meeting still hangs in the air as a cautionary tale. That stigma is shifting, slowly. Investors are pouring money into psychedelic biotech. Cities and states are loosening laws. The conversation around psychedelics, addiction recovery, and mental health is moving from fringe to mainstream faster than almost anyone predicted ten years ago. Still, the most thoughtful people in this world tend to caution against treating mushrooms as a life hack. The traditions that have used these plants for centuries don’t talk about productivity. They talk about humility, listening, and being changed by something larger than yourself. Worth holding both ideas at once. If you’ve read this far, you’re probably not looking for a hot take. You’re trying to figure out whether any of this is for you. A few honest suggestions: For readers who want to take this further, a range of curated psilocybin and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, decide it slowly. These are old medicines moving through a very new world, and the people who get the most out of them tend to be the ones who took their time getting in.
Ibogaine and 5-MeO-DMT for PTSD: What Veterans and Trauma Survivors Should Know
Some wounds don't show up on an x-ray. The kind that wake you at 3am with your chest pounding, the kind that flatten your motivation for months at a stretch, the kind that turn a person who used to laugh easily into someone who flinches at loud noises in a grocery store. Complex trauma is sneaky like that. And for a lot of people — especially combat veterans, abuse survivors, and folks who've stacked enough hard years to lose count — the standard menu of SSRIs and weekly talk therapy just isn't moving the needle. That's where the conversation around ibogaine and 5-MeO-DMT keeps coming up. Two very different psychedelics, both being studied seriously for PTSD and trauma-based conditions, both delivering results in days that conventional treatment sometimes can't deliver in years. I want to walk you through what they actually are, what the research is showing, what a session looks like from the inside, and — honestly — what you should be cautious about before booking anything. PTSD is one of the most treatment-resistant conditions in psychiatry. The frontline options — sertraline, paroxetine, prolonged exposure therapy, EMDR — help some people meaningfully. They fail a lot of others. Studies of military populations consistently show drop-out rates from exposure-based therapy hovering around a third, and even those who finish often retain a clinical PTSD diagnosis afterward. The picture gets darker inside Special Operations communities. Repeated deployments, blast exposure, and the cumulative weight of doing extremely violent work for years produce a kind of layered trauma that doesn't unwind easily. Studies have estimated PTSD prevalence in SOF personnel at roughly three times the rate found in conventional military populations, often tangled up with traumatic brain injury, sleep collapse, and substance use. When weekly outpatient therapy can't touch that, people start looking elsewhere. And here's the thing — many of them are finding their way to clinics in Mexico, Costa Rica, the Netherlands, and Portugal, often quietly, often after their own friends have come back changed. Word of mouth in those communities travels fast. Ibogaine is the principal alkaloid in the root bark of Tabernanthe iboga, a shrub used for centuries in the Bwiti tradition of Gabon and Cameroon. In ceremonial Bwiti contexts, the medicine is taken in initiatory rites — meetings with ancestors, encounters with one's own history, the kind of psychological reckoning that Western frameworks have no clean vocabulary for. In a Western clinical or retreat setting, an ibogaine session typically lasts somewhere between 18 and 36 hours. That's not a typo. It is long. People often describe the first many hours as a kind of waking dream — a panoramic replay of autobiographical memory, with emotional charge restored to events the conscious mind had filed away or papered over. Then comes a quieter introspective phase, sometimes lasting a full day, where insights settle and the nervous system starts to recalibrate. What makes ibogaine particularly interesting for trauma and addiction is its apparent capacity to interrupt entrenched patterns. Opioid users have reported withdrawal symptoms collapsing within hours and cravings remaining absent for weeks or months. Trauma survivors describe being able to look at painful memories without the usual freeze response — as if the wiring around the memory has loosened. Mechanistically, researchers point to its action on multiple receptor systems, NMDA modulation, and a metabolite called noribogaine that lingers in the system and may explain the extended afterglow. I need to be plain here, because some online write-ups gloss over this. Ibogaine carries cardiac risk. It can prolong the QT interval on an EKG, which in rare cases has triggered fatal arrhythmias. Deaths associated with ibogaine are almost always linked to pre-existing heart conditions, undisclosed drug interactions, or sessions run without proper medical screening and monitoring. Any serious provider will require: If a retreat tells you to just show up and trust the process, walk away. This isn't a substance to take casually or in a setting that treats medical screening as paperwork. 5-MeO-DMT is a different animal entirely. Naturally occurring in certain plants and in the venom of the Sonoran Desert toad (Incilius alvarius), it produces one of the shortest and most intense psychedelic experiences known. Inhaled or vaporized, the experience peaks within a minute or two, and the whole thing is often over inside 20 minutes. What happens during those 20 minutes is famously hard to articulate. People describe it as ego dissolution, white-out, a sense of merging with everything, the collapse of the boundary between observer and observed. It is not a journey through landscapes in the way ayahuasca or psilocybin can be — it is more like the floor falling out from under the concept of being a separate self at all. Many people cry. Many people are silent for hours afterward. Some come back saying it was the single most important experience of their life. Others come back rattled and need real integration support. For trauma, the proposed mechanism is something like a hard reset. The default mode network — the brain region implicated in rumination, self-referential thought, and many trauma loops — appears to go quiet during the peak. When it comes back online, some of the rigid patterning seems to have loosened. Combined with skilled integration in the days that follow, that loosening is what lets people work with memories that had previously been unworkable. The most-cited study in this space looked at U.S. Special Operations veterans who traveled to a clinic outside the U.S. for combined ibogaine and 5-MeO-DMT treatment. Researchers at Ohio State analyzed outcomes from 86 of them. The findings were striking: large, statistically significant reductions in PTSD symptoms, depression, anxiety, and insomnia, with improvements in cognitive flexibility holding at the six-month follow-up. Roughly half the veterans described the experience as the single most spiritually significant event of their lives. About 40% considered it the most psychologically insightful event they'd ever had. That's a remarkable signal from a population that, by definition, has tried many other interventions first. That said — observational studies of self-selected participants traveling to clinics aren't the same as randomized controlled trials. The research community is appropriately cautious. More rigorous trials are underway. The early signal is genuinely promising, but it's still early. Most reputable clinics offering this pair of medicines run a structured multi-day protocol. The shape varies, but the typical arc looks like this: The total cost of a properly run program usually lands somewhere between $8,000 and $15,000, and longer or more medicalized programs can cost more. That's not a small number. It also reflects what's actually being delivered — medical staff, screening, facilitation, accommodation, food, and integration support over the better part of a week. This is where I'd slow down hardest if I were you. The legal gray zones around these medicines mean the quality range is enormous. Some clinics are doing extraordinary, careful, life-changing work. Others are dangerously casual. A few warning signs and good signs: Ask hard questions. Reputable providers welcome them. The ones who get defensive are telling you something useful. Honestly, sometimes. Not always. Psychedelic-assisted treatment isn't a magic eraser, and people who go in expecting one tend to come out disappointed. What it can do — when the medicine, the setting, and the integration are all in alignment — is interrupt patterns that have been frozen for a very long time and give you a workable opening to do the slower work of healing. If you're on multiple psychiatric medications, if you have a personal or family history of psychosis, if you have a heart condition, or if you're in acute crisis, this is probably not the right starting point. If you've done the conventional work, you're stable enough to travel and engage, and you've got support waiting for you when you come home — then it might be worth seriously considering. For readers who want to explore this further, a curated range of ibogaine and 5-MeO-DMT retreats can be browsed on our marketplace here. Take your time, ask the hard questions, and choose the place that treats your safety and your story with the seriousness both deserve.
Oregon Psilocybin Law: What's Legal, What Isn't, and Why It Matters for Retreat-Seekers
A few years back, a small herbal shop in Portland made the kind of headlines that confuse the hell out of anyone trying to understand where psychedelics actually stand in the United States. People lined up around the block. They filled out questionnaires. They walked out with bags of psilocybin mushrooms — varieties with names like Penis Envy and Albino Golden Teacher — paying somewhere around $85 to $95 for seven grams. The shop framed itself as Oregon's first licensed psychedelic dispensary. It wasn't. Not even close. And the gap between what was happening on that sidewalk and what Oregon's psilocybin law actually permits is exactly the kind of confusion that trips up people researching plant medicine, master plants, and psychedelic retreats. If you're weighing whether to spend real money on a retreat, you need to understand this landscape clearly — because the difference between a legal therapeutic container and an unregulated transaction has real consequences for your safety, your wallet, and your healing. Oregon passed Measure 109 — the Oregon Psilocybin Services Act — back in November 2020. It was the first state-level psilocybin law of its kind in the country, and it was a genuine milestone for psychedelic-assisted recovery. But the measure didn't do what a lot of casual readers assume it did. It did not decriminalize mushrooms. It did not legalize recreational sale. It did not turn psilocybin into something you can pick up alongside your kombucha. What it created was a tightly regulated framework for supervised therapeutic use. Under Measure 109, psilocybin can only be consumed at a licensed service center, in the presence of a licensed facilitator, by someone who has gone through a preparation session. There is no take-home model. There is no retail counter. There is no path — present or planned — for buying mushrooms over the counter and walking out with them. Sam Chapman, who runs the Healing Advocacy Fund, put it about as plainly as anyone can: nothing in Measure 109, and nothing in any other Oregon law, permits the retail sale of psilocybin mushrooms. Not today, not in the future as the law is currently written. The state's licensed services exist because Oregonians dealing with depression, anxiety, and addiction stand to benefit from psilocybin — but only when the therapy is delivered safely, with screening, integration, and a trained guide. The Shroom House situation is a useful case study in what happens when commercial momentum runs ahead of regulation. Customers were asked to join a so-called "Shroom House Society," show two forms of ID, prove they were over 21, and fill out a questionnaire that asked about mental health history. From a distance, that paperwork looks vaguely clinical. Up close, it's a loyalty card with extra steps. A reporter who walked in was apparently buying within five minutes of finishing the form. A former employee eventually went to local news and said management had told staff the shop was the first medically sanctioned psychedelic retailer in the state. It wasn't. The Oregon Health Authority hadn't even started issuing facilitator and service-center licenses yet. The shop was operating in a legal vacuum that didn't actually exist — psilocybin is still a Schedule I substance under federal law, and at the time, no Oregon entity had authority to sell it commercially under state law either. The honest takeaway here isn't outrage. It's the recognition that wherever there's genuine therapeutic demand and unclear regulation, opportunists will find the seam. For anyone researching psychedelics seriously — especially anyone hoping to use them for addiction or depression — knowing the difference between an above-board therapeutic container and a guy with a storefront is essential. Compare the Portland storefront with what an actual psychedelic retreat involves and the contrast becomes obvious. Whether we're talking about psilocybin services in Oregon, ayahuasca ceremonies in the Peruvian Amazon, ibogaine in Mexico, or San Pedro in the Andes, the legitimate end of this world shares a common shape: None of that is what happens when you buy mushrooms over a counter and take them home. That's not a retreat. That's not therapy. That's a transaction, and any framing that suggests otherwise is doing the medicine — and the people it might help — a disservice. The honest answer is: increasingly, the evidence says yes — but the conditions matter enormously. Clinical research on psilocybin for alcohol use disorder, ibogaine for opioid dependence, and ayahuasca for various substance and behavioral addictions has been quietly accumulating for two decades now. The trial results aren't fringe anymore. Johns Hopkins, NYU, Imperial College London — serious institutions are publishing serious data on psychedelic-assisted recovery, and the early signal is that these compounds can interrupt patterns that years of conventional treatment couldn't budge. That said, master plants and synthetic psychedelics aren't magic. They're powerful tools that work best when held inside a real therapeutic process. Someone in active addiction who buys mushrooms at a storefront and dips in alone is not running the same intervention as someone going through a screened, prepared, facilitated session. The substance might be identical. The outcome rarely is. Set and setting — that old Leary phrase — turns out to be more than a slogan. It's most of the medicine. This is why the legal framework Oregon is building, slow and frustrating as it can feel, actually matters. A regulated facilitator model creates the conditions under which psilocybin's therapeutic potential can show up reliably. A storefront free-for-all creates the conditions under which people get hurt and the whole movement gets a black eye. Here's the practical takeaway. If you're someone quietly considering plant medicine — for a stuck depression, a trauma you can't seem to metabolize, an addiction that has outlasted every other intervention — the Portland story is a useful warning. The space is filling up with operators whose understanding of safety ranges from excellent to nonexistent. Marketing language and clinical legitimacy are not the same thing. A few things worth checking before you commit money or travel: The psychedelic-assisted recovery field is in a strange adolescent phase right now. The laws are catching up unevenly. The science is racing ahead. And in the gap between the two, both genuine healing centers and outright opportunists are setting up shop. Your job as a researcher — and a potential participant — is to tell them apart. If you've read this far and want to keep exploring legitimate options, a range of vetted psilocybin and plant-medicine retreats can be browsed on our marketplace here. Take your time with the decision. The medicine isn't going anywhere, and the right container is worth waiting for.
Vancouver's Magic Mushroom Dispensaries: Civil Disobedience or Legalization Strategy?
Walk down certain blocks of East Vancouver and you'll spot something that probably shouldn't exist under federal law: storefronts openly selling psilocybin. Chocolates, capsules, dried caps in glass jars. No back rooms, no whispered passwords. Just a counter, a price list, and a clerk who'll happily explain the difference between a microdose and what they call a “heroic” one. It's strange. It's a little brazen. And if you've been following the slow, uneven march of psychedelics from underground curiosity to clinical research darling, it's also very, very familiar. Because this exact playbook — open a shop, dare the authorities to shut you down, force the conversation — is how Canada ended up legalizing cannabis. Now a handful of activists are running the same experiment with magic mushrooms, and the rest of us get to watch in real time. Psilocybin is a controlled substance under Canadian federal law. Selling it is illegal. And yet, in Vancouver, a small but growing cluster of dispensaries does exactly that — out in the open, with signage, social media accounts, and customer reviews. The most visible operator is Dana Larsen, a longtime drug-policy activist who runs the Medicinal Mushroom Dispensary out of the same space as his Coca Leaf Café. He started selling psilocybin chocolates and capsules to walk-in customers a few years back, and he's been pretty transparent about his strategy: keep selling, get noticed, force the government to either crack down hard or move toward regulation. So far the government has done neither, which is its own kind of answer. Other shops have followed. Some opened during the pandemic to make up for lost revenue from cannabis or other businesses. A few are run by people who genuinely believe psilocybin should be available for therapeutic use and are tired of waiting for Ottawa to catch up. The Vancouver Police have said mushroom prosecutions aren't a top priority. City Hall has sent some sternly worded letters. The shops are still open. Here's the thing about Vancouver: this city has been a testing ground for drug-policy civil disobedience for decades. Illegal cannabis dispensaries operated openly there from at least 2015, with the city eventually creating a municipal licensing system — even though selling weed was still federally illegal at the time. Three years later, Canada legalized recreational cannabis nationwide. Was that legalization the direct result of grey-market shops? Probably not entirely. But the shops normalized the conversation. They made it impossible for politicians to pretend the demand wasn't there. They gave the public a chance to see, for years, that the sky didn't fall. By the time Parliament got around to writing legislation, the cultural battle was largely over. The mushroom dispensary owners are betting the same dynamic will play out again. The bet isn't crazy. Psilocybin research is moving fast — clinical trials at major universities, Health Canada granting individual exemptions for people with terminal illness or treatment-resistant depression, and a steady drip of mainstream media coverage that treats the molecule as medicine rather than menace. The legal frame is wobbling. Someone was always going to push. Let's pause on the medical claim, because it matters. There's now a real body of clinical evidence suggesting that psilocybin — typically administered in larger, supervised doses alongside psychotherapy — can produce meaningful and sometimes lasting reductions in depression and anxiety, including for people who haven't responded to standard treatments. It's also being studied for addiction, end-of-life distress, and a handful of other conditions where the conventional pharmaceutical toolkit has been underwhelming. This isn't fringe stuff anymore. It's published in peer-reviewed journals. It's drawing real money into psychedelic biotech. A psychedelic-focused exchange-traded fund launched on a Canadian exchange a few years ago, which is roughly the most boring possible signal that a thing has gone mainstream. Microdosing — taking sub-perceptual amounts on a regular schedule — is a different story. The popular case for it has run well ahead of the data. Some researchers find modest mood and creativity effects; others find that most of what people report is placebo. If you're considering microdosing for a specific mental health issue, the honest answer is: the jury's still out, and a properly supervised larger-dose session may have far stronger evidence behind it. Even with the shops operating openly, psilocybin remains illegal to sell or possess in Canada outside narrow exemptions. Health Canada does grant individual access through its Special Access Program, and there's a Section 56 exemption pathway, but both processes are slow, paperwork-heavy, and require specific medical circumstances. A not-for-profit called TheraPsil has spent years helping patients — especially those facing terminal diagnoses — navigate the bureaucracy. Many people give up and turn to grey-market shops or underground guides instead. In the United States, the picture is more fragmented. Federally, psilocybin is Schedule I. But Oregon has rolled out a regulated psilocybin services program, Colorado has decriminalized personal possession and is building out its own framework, and a growing list of cities — Denver, Oakland, Seattle, Detroit, several others — have effectively deprioritized enforcement. None of this makes it legal to buy mushrooms at a shop the way Vancouverites can. But the legal terrain is shifting fast enough that anything written about it has a short shelf life. If you've read this far, there's a decent chance you're not just curious about Canadian drug policy. You're weighing whether a psychedelic experience — mushrooms, ayahuasca, something else — might actually help with something specific. Depression that won't budge. A drinking problem. Grief. A sense that you've been on autopilot for years and can't find the off switch. A few honest things to consider before you walk into any dispensary or book any retreat: Vancouver's mushroom shops won't be the last act in this story. Whether they get raided, regulated, or quietly absorbed into a future legal framework, they've already done some of the work activists wanted them to do — they've made psilocybin visible, debatable, and increasingly unavoidable as a policy question. Other cities will follow. Some governments will move quickly; others will dig in. For individuals trying to figure out whether plant medicine has a real role in their own life, the better path is usually slower than walking into a shop. It involves reading widely, talking to people who've done the work, screening yourself for real medical risks, and choosing a setting with trained facilitators and a clear integration plan. Retreats — especially ones in jurisdictions where the practice is legal or traditionally protected — remain the most evidence-supported way most people access these experiences. If you're starting that research, a range of curated psilocybin and plant-medicine retreats can be explored on our marketplace here. The Vancouver dispensaries are an interesting symptom of where the culture is going. They're probably not where your own story should start.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
